GLP-1/Weight Loss

Resalis Therapeutics poaches a top clinical leader from Novo Nordisk to steer its novel RNA-based obesity drug, RES-010, through clinical trials.

As iBio heads to a key investor conference, its AI-driven antibody platform aims to solve the GLP-1 paradox: achieving sustainable weight loss by preserving muscle.

A new report reveals a shift from transformation to restoration, as GLP-1 drugs and an aging population create a new frontier for the plastic surgery industry.

Telehealth firm NexLife is disrupting the GLP-1 market with flat-rate pricing and novel sublingual options, a strategy aimed at accessibility amid regulatory scrutiny.

Samsung Biologics is raising KRW 3 trillion to buy a peptide specialist and build a mega-campus. It's a bold play that trades short-term dilution for long-term dominance.

A free online calculator for an experimental drug seems trivial. But it reveals the hidden operational layer where scientific breakthroughs are forged.

Biomea Fusion's new trial combines its drug icovamenib with semaglutide, aiming not just for weight loss, but to solve a major side effect: muscle loss.

With the appointment of Dr. Jeffrey Sherman, Kalohexis signals a major push to conquer the challenging metabolic disease market with its novel pipeline.

As GLP-1 drugs reshape bodies and markets, a new support ecosystem emerges. Menu-Order AI's hire of a Harvard physician signals a critical shift in wellness tech.

With its lead obesity drug in late-stage trials and a Novo Nordisk veteran newly hired, Structure Therapeutics is making a calculated play for the oral GLP-1 crown.

Biotech firm MetaVia reports progress on its obesity drug DA-1726, with patients reaching high doses. Promising early data sets the stage for a pivotal Q4 readout.

A startup led by ex-Novo Nordisk execs plans a reverse takeover to fund its made-in-Canada generic Ozempic, aiming to disrupt a C$3.5B market.

Hims & Hers' new AI-powered app promises a revolution in women's health. But can it navigate fierce competition, regulatory hurdles, and data privacy scandals?

U.S. sugar demand remains surprisingly strong, but a perfect storm of health trends and weight-loss drugs like Ozempic threatens a $55 billion upheaval.

An FDA panel's nod to controversial peptides seems to validate Hydreight's long-term strategy. But a closer look reveals a long road and a deep data gap.

Gaxos.ai's strategic pivot away from gaming has fueled a massive revenue surge. But beyond the headline numbers, can it achieve profitability and prove its AI identity?

A perfect storm of wonder drugs, AI-driven billing, and flawed policy is pushing employer health costs to a 15-year high, forcing a radical rethink of benefits.

Small biotech Veru Inc. is betting its future on improving blockbuster weight-loss drugs, targeting the hidden cost of muscle loss in a billion-dollar market.

Viking Therapeutics' appointment of digital health veteran Dorothy Gemmell signals a pivotal shift from lab to market in the crowded weight-loss field.

A new report reveals a seismic shift in drug manufacturing. Forget massive factories; the real power now lies with a handful of specialists building our medical future.